About Mediator of RNA polymerase II transcription subunit 6
Mediator of RNA polymerase II transcription subunit 6 (MED6) is a protein
from Homo sapiens identified by UniProt accession
O75586, 246 residues long.
MolForge cross-references it against 0 known binders and
12 disease associations.
Target properties
| Protein name | Mediator of RNA polymerase II transcription subunit 6 |
|---|
| UniProt accession | O75586 |
|---|
| Gene | MED6 |
|---|
| Organism | Homo sapiens |
|---|
| Length | 246 residues |
|---|
| Molecular weight | — |
|---|
| EC numbers | — |
|---|
| Target class | UNCLASSIFIED |
|---|
| Subcellular location | — |
|---|
| Keywords | — |
|---|
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
|---|
| Druggability score | — |
|---|
| Pocket score | — |
|---|
| Max clinical phase | — |
|---|
Disease associations (12)
Diseases linked to this target (Open Targets).
- neurodegenerative disease · score 0.51
- PHF-tau measurement · score 0.18
- late-onset Alzheimers disease · score 0.14
- prostate carcinoma · score 0.09
- low density lipoprotein cholesterol measurement · score 0.04
- response to statin · score 0.03
- systemic juvenile idiopathic arthritis · score 0.01
- hepatocellular carcinoma · score 0.01
- non-small cell lung carcinoma · score 0.01
- neoplasm · score 0.00
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
|---|
| AF-O75586-F1 | alphafold | PREDICTED | 75.56 | — |
Amino-acid sequence (246 residues)
MAAVDIRDNL LGISWVDSSW IPILNSGSVL DYFSERSNPF YDRTCNNEVV KMQRLTLEHL NQMVGIEYIL LHAQEPILFI IRKQQRQSPA QVIPLADYYI IAGVIYQAPD LGSVINSRVL TAVHGIQSAF DEAMSYCRYH PSKGYWWHFK DHEEQDKVRP KAKRKEEPSS IFQRQRVDAL LLDLRQKFPP KFVQLKPGEK PVPVDQTKKE AEPIPETVKP EEKETTKNVQ QTVSAKGPPE KRMRLQ
Explore Mediator of RNA polymerase II transcription subunit 6 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets